The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced non-small cell lung cancer (NSCLC) with EGFR mutations.Patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Stéphanie Héon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney, Gregory Joseph Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson
Médium: Artigo
Jazyk:angličtina
Vydáno: 2012
On-line přístup:https://doi.org/10.1158/1078-0432.ccr-12-0357
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1158/1078-0432.ccr-12-0357

Podobné jednotky